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Background: Bullous pemphigoid (BP) is an autoimmune 
subepidermal bullous disease associated with autoantibodies 
against BP180 and BP230. Enzyme-linked immunosorbent 
assay (ELISA) is a sensitive tool for the detection of immuno-
globulin G (IgG) anti-BP180 and anti-BP230 autoantibodies. 
Objective: The aim of this study was to evaluate the use-
fulness of ELISA for diagnosing and monitoring the disease 
activity of BP. Methods: We evaluated serum IgG levels of 
anti-BP180 and anti-BP230 autoantibodies in 47 BP patients, 
16 epidermolysis bullosa aquisita patients, and 15 healthy 
volunteers using ELISA. Through retrospective review of the 
medical records, the clinical characteristics of BP including 
disease activity, duration, pruritus severity and peripheral 
blood eosinophil counts were assessed. Results: The 
sensitivity of BP180 ELISA was 97.9%, BP230 ELISA 72.3%, 
and a combination of the two was 100%. The specificity of 
BP180 ELISA was 90.3%, BP230 ELISA 100%, and a 
combination of the two was 90.3%. BP180 ELISA scores 
showed strong associations with disease activity, pruritus 
severity, peripheral blood eosinophil counts, and disease 
duration, whereas BP230 ELISA scores did not. Conclusion: 
BP180 and BP230 ELISAs are highly sensitive methods for 
the diagnosis of BP, and BP180 ELISA, in particular, is a 
sensitive tool for monitoring the disease activity of BP. (Ann 
Dermatol 24(1) 45∼55, 2012)
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INTRODUCTION
Bullous pemphigoid (BP) is an autoimmune subepidermal 
bullous disease that is clinically characterized by genera-
lized tense blisters arising on apparently normal or erythe-
matous skin and even mucous membranes1. Immunopa-
thologically, BP has been characterized by tissue-bound 
and circulating immunoglobulin G (IgG) autoantibodies 
against the antigen on the basement membrane zone 
(BMZ) of stratified epithelia2. Direct immunofluorescence 
(IF) study of perilesional skin reveals linear deposition of 
IgG and/or C3 along the BMZ. Indirect IF study using salt 
split skin demonstrates serum IgG autoantibodies bound 
to the epidermal side of the salt split skin. These autoanti-
bodies in BP are known to react with two components of 
the hemidesmosome, BP230 and BP1803,4.
BP180, also known as type XVII collagen or BP antigen 2, 
is a 180 kDa transmembranous glycoprotein that ultra-
structurally spans the lamina lucida before kinking back 
from the lamina densa into the lamina lucida. It comprises 
a globular cytoplasmic domain and a long C-terminal 
extracellular component consisting of 15 discontinuous 
collagenous domains separated by 16 non-collagenous 
(NC) domains5-7 (Fig. 1A). This protein contributes to the 
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Fig. 1. Schematic diagrams depicting
the structure and regions of the 
recombinant proteins (marked by the
blue line) of human BP180 (A) and 
BP230 (B) utilized in this enzyme- 
linked immunosorbent assay study. 
NH2: N-terminus, NC16A: 16th non-
collagenous domain, COOH: C- 
terminus, BP: bullous pemphigoid.
assembly and stabilization of hemidesmosomes8,9. The 
16th NC (NC16A domain of the BP180 ectodomain, the 
NC16A domain, has been identified as the immunodomi-
nant region of BP180 in patients with BP, mucous mem-
brane pemphigoid (MMP), and pemphigoid gestationis 
(PG)10-14.
The other major target antigen in BP is BP230 (also called 
BPAG1), a 230 kDa intracellular constituent of the hemi-
desmosomal plaque. BP230 belongs to the plakin family 
proteins and is considered to play an important role in the 
structural stability of hemidesmosomes. It comprises a 
central α-helical coiled-coil region flanked by two globular 
end domains and several distinct subregions15,16 (Fig. 1B). 
The N-terminal and C-terminal domains of BP230 are con-
sidered to be important in interactions with other hemi-
desmosomal transmembrane proteins such as BP180, β4 
chain of α6β4 integrin, and keratin intermediate filaments, 
whereas the central α-helical coiled-coil domain apparen-
tly plays a role in its structural stability and self-assem-
bly17-19. In addition to BP, reactivity to BP230 may be 
found in patients with paraneoplastic pemphigus and less 
frequently in those with MMP and PG12,20-22.
Autoimmune blistering dermatoses comprise various dis-
eases that are characterized by autoantibodies to structural 
components of the skin and mucous membranes. For 
immunobullous disorders, accurate diagnosis is important 
because each of them shows different prognosis and 
requires specific treatment modality. Nevertheless, in most 
cases, an autoimmune bullous disease cannot be diagno-
sed based on clinical and/or histologic finding alone and 
requires the detection of tissue-bound and circulating 
autoantibodies. Indirect IF study using normal human skin 
or monkey esophagus substrates is the currently accepted 
method for detecting autoantibodies in BP. However, the 
method greatly depends on the operator’s skill and is 
difficult to standardize. Immunoblotting and immunopre-
cipitation can also be used to identify the target antigens. 
However, they are both time-consuming qualitative tech-
niques and thus are not suitable for routine screening of a 
large number of serum samples. 
Enzyme-linked immunosorbent assay (ELISA) was perfor-
med on 96-well plates to allow 48 samples to be tested in 
duplicate. This assay is fairly simple, requiring only 5 μM 
of serum and is easily completed within a day, allowing 
the analysis of a large number of samples in a relatively 
short time. The data are objective as the optical density 
(OD) of each well is automatically read and expressed as a 
numerical value from a continuous scale. Similar to immu-
noblotting and immunoprecipitation, but unlike indirect 
IF, ELISA data provides information on antigen identity 
and allow differentiation between autoimmune subepider-
mal blistering diseases. In addition, it has the advantage of 
providing reproducible, quantitative data. Quantitative 
data from this assay may ultimately prove to be beneficial 
in guiding patient management.
Since synthetic or recombinant BP180 and BP230 frag-
ments have become available, ELISAs based on recom-
binant proteins such as the NC16A domain alone or asso-
ciated with other epitopes have been developed for the 
detection of these autoantibodies in patient sera23-27. The 
majority of BP sera have been revealed to react with the 
BP180-NC16A domain, and ELISA systems using recom-
binant BP180 had sensitivity ranging from 80% to 95%28. 
Furthermore, the levels of circulating IgG autoantibodies 
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Table 1. Disease activity score of bullous pemphigoid
Extent of disease (0∼7) Intensity of therapy (1∼6)
Number of following body areas where the skin lesion involved (0∼6)
  Scalp, face and neck, chest and abdomen, back, arm, leg
With the involvement of the oral mucosa: 1 
MPD 8 mg＞: 1
8∼24 mg: 2
24 mg＜: 3
Dapsone, minocycline, nicotinamide: 1 
MPD pulse, IVIG: 2
Disease severity grade according to disease activity score 
　: mild: 1∼4, moderate: 5∼8, severe: 9∼13
MPD: methylprednisolone, IVIG: intravenous immunoglobulin.
in BP patients detected via ELISA have been linked to the 
clinical activity of the disease25,29-31. BP230 ELISA has also 
been developed, and its sensitivity in BP patients ranges 
from 60% to 70%32-34. An extensive serological study 
utilizing an ELISA system with baculovirus-derived eukar-
yotic BP230 recombinant proteins confirmed that both the 
N-terminus and C-terminus of BP230 are major immuno-
dominant regions targeted by the IgG autoantibody in 
BP35. 
The purpose of this study was to evaluate the two 
commercially available ELISA systems (MBL Co., Nagoya, 
Japan) for detection of autoantibodies of BP180 and 
BP230 practically as routine diagnostic tests for BP and to 
address the potential relationship between autoantibody 
profiles and distinct clinical features and severity in BP 
patients. 
MATERIALS AND METHODS
Patients and controls
We retrospectively evaluated serum samples from 47 pa-
tients (20 men, 27 women; mean age 71.5±14.7, range 
30∼94) who were diagnosed with BP and treated bet-
ween May 2008 and November 2010 at the Department 
of Dermatology, Yonsei University College of Medicine. 
At the time of sample collection, 17 patients were on 
systemic immunosuppressive treatment. BP was diagno-
sed on the basis of the following criteria: characteristic 
clinical findings of pruritic plaques and tense blisters of 
the trunk and extremities without formation of scars or 
milia; histological evidence of subepidermal blisterings 
with numerous infiltrating polymorphonuclear cells, mainly 
eosinophils, along the basement membrane and within 
the blister cavities; evidence of linear deposits of IgG 
and/or C3 at the dermal-epidermal junction by direct IF; 
and evidence of circulating anti-basement membrane 
autoantibodies by indirect IF, more specifically, evidence 
of their deposit on the epidermal side of salt split skin. All 
patients’ sera showed circulating IgG bound to the 
epidermal side of the salt split skin with titers ≥1：10. 
Forty-two BP patients presented skin lesions of BP without 
any mucous membrane involvement, and five other BP 
patients showed both skin and mucosal lesions without 
residual scarring. Sera from 15 healthy volunteers (9 
males, 6 females) and 16 epidermolysis bullosa aquisita 
(EBA) patients (5 males, 11 females), whose diagnosis was 
confirmed by clinical criteria, routine histology, immuno-
pathology, and ELISA reactivity with type VII collagen, 
were tested. 
Serum samples were obtained from 5 successfully treated 
BP patients before treatment and after complete remission. 
“Complete remission” was defined as the absence of skin 
lesions for more than 1 month. Serial serum samples at 3 
different time points during systemic treatment were 
collected from one patient, and were evaluated for auto-
antibody titers against BP180 and BP230 by ELISA to inves-
tigate the relevance between antibody titers and clinical 
disease activity. 
Clinical and laboratory assessment
To investigate the relationship between BP180 and BP230 
ELISA scores and the disease characteristics of BP, sero-
logical, pathological, and clinical records of BP patients 
were examined. Among 47 BP patients, two patients were 
excluded for insufficient information on their medical 
records. With regards to disease characteristics, we exami-
ned four different variables: disease activity, disease dura-
tion, pruritus severity, and peripheral blood eosinophil 
counts.
To assess clinical disease activity of BP, we used a scoring 
system which was a modified version of a pemphigus 
scoring system designed by Herbst and Bystryn36. Disease 
activity was calculated by adding scores for the extent of 
disease and intensity of treatment at the time of sample 
collection. The disease extent was graded from 0 to 6＋ 
based on the number of body areas involved. With the 
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Fig. 2. Scatter plot representation of BP180 (NC16A domain, 
represented in black dots) and BP230 (C- and N-terminal 
recombinant proteins, represented in red dots) ELISA results 
(index value). Forty-seven BP sera and 31 control sera (16 EBA
sera and 15 healthy volunteer sera) were examined. A dashed 
line indicates the cut-off value (BP180, 9 index; BP230, 9 index).
The arithmetic means of index value are indicated by a line.
Index value=(optical density [OD] of tested serum－OD of 
negative control)/(OD of positive control－OD of negative con-
trol)×100. Cut-off values were determined based on the manu-
facturer’s recommendation. BP: bullous pemphigoid, EBA: 
epidermolysis bullosa aquisita, ELISA: enzyme-linked immuno-
sorbent assay, NC16A: 16th non-collagenous domain.
involvement of the oral mucosa, a score of 1＋ was assig-
ned. The intensity of therapy was graded from 0 to 5＋ 
based on the corticosteroid dose and combination therapy 
required to control the disease. A score from 0 to 3＋ was 
given according to the dose of corticosteroids (expressed 
in mg/day of methylprednisolone). If a combination thera-
py such as minocycline, nicotinamide powder or dapsone 
was used, a score of 1＋ was assigned. If treatment with 
pulsed methylprednisolone or intravenous immunoglobulin 
was done, a score of 2＋ was recorded. The disease 
activity of BP patients was graded on a 1∼13 scale. BP 
disease severity was further classified as mild, moderate or 
severe based on the disease activity score of 1∼4, 5∼8 or 
9∼13, respectively (Table 1). The mean disease activity 
score of 45 BP patients was 6.8. The mild disease group 
included 10 patients, moderate disease group included 23 
patients, and the severe disease group included 12 patients.
The interval between the onset of symptoms and the time 
when the serum samples were obtained was defined as 
the disease duration. In 45 BP patients, the mean disease 
duration was 316.7±699.1 (range, 7∼4,380) days. To 
compare the ELISA scores, BP patients were initially divi-
ded into two groups based on disease duration (＜3 mon-
ths and ≥3 months) as attempted in a previous report25. 
Owing to the lack of satisfactory methods for quantifying 
pruritus severity, the severity of pruritus was scored based 
on the dose of antihistamine drug, which was prescribed 
to control pruritus at the time of sample collection, as 
follows: none (0) when no antihistamine drug was prescri-
bed, mild (1) when one or two kinds of antihistamine drug 
were prescribed, and severe (2) when more than two kinds 
of antihistamine drug were prescribed. The no pruritus 
group included 19 patients, mild pruritus included 19 
patients, and severe pruritus group included 7 patients.
Peripheral blood eosinophil count was also evaluated at 
the time of sample collection. Peripheral blood eosinophil 
count was elevated in 17 BP patients (38%). The mean 
blood eosinophil count of 45 BP patients was 1020.6± 
1557.5 (range, 0∼7330)/μl.
ELISA
Anti-BP180 and anti-BP230 IgG autoantibody titers were 
measured using commercially available ELISA kits (MBL 
Co.) which are coated with recombinant proteins encom-
passing either the C- and N-terminus domain of BP230 or 
the NC16A domain of BP180. Following manufacturer’s 
instruction, serum samples were diluted to 1：100 in 
assay diluent. Diluted serum samples were added to the 
wells. After rinsing off any unbound substances, peroxidase- 
conjugated goat polyclonal anti-human IgG antibodies 
were added to the wells. Development was performed 
using a microplate reader set to 450 nm to reflect the level 
of anti-BP180 and anti-BP230 autoantibodies bound in the 
initial step in each sample. 
ELISA quantification
To compare results from different plates, test sample ODs 
were adjusted relative to the positive and negative control 
samples supplied in each kit. The mean OD of duplicate 
wells was calculated. The index value of each tested serum 
was defined by the following formula: index=(OD of 
tested serum－OD of negative control)/(OD of positive 
control－OD of negative control)×100. A cutoff ELISA 
value of 9 U/ml was used (≥9.0 U/ml being a positive 
result) on the basis of the manufacturer’s recom-
mendation.
Statistical methods
The diagnostic accuracy of the ELISA in terms of the 
sensitivity and specificity was presented. ELISA scores 
were plotted by disease duration, disease severity grade 
and pruritus severity grade groups and compared between 
groups using Wilcoxon rank-sum test. The relationships of 
ELISA scores with other clinical variables were measured 
by Spearman correlation coefficient (r). Group comparison 
for categorical variables was done by the chi-square test or 
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Table 2. Sensitivity and specificity of BP180 ELISA and BP230
ELISA
ELISA Sensitivity (n=47) Specificity (n=31)
BP180 97.9 (46/47) 90.3 (28/31)
BP230 72.3 (34/47) 100 (31/31)
BP180＋BP230 100 (47/47) 90.3 (28/31)
Values are presented as % (n). BP: bullous pemphigoid, ELISA:
enzyme-linked immunosorbent assay.
Fig. 3. Correlation between (A) BP180 ELISA scores and disease activity scores, (B) BP230 ELISA scores and disease activity scores, 
(C) BP180 ELISA scores and blood eosinophil counts, (D) BP230 ELISA scores and blood eosinophil counts in BP patients. BP: bullous 
pemphigoid, ELISA: enzyme-linked immunosorbent assay.
Fisher’s exact test. All statistical analyses were performed 
by SAS version 9.2 (SPSS Inc., Chicago, IL, USA) using the 
alpha level of 0.05 to denote significance.
RESULTS
Detection of IgG reactivity against BP180 and BP230 
using ELISA 
To assess the reactivity of BP sera and control sera against 
the BP180 and BP230, 47 BP sera, 16 EBA sera and 15 
sera from normal healthy individuals were tested using 
commercially available ELISA kits. No association was 
observed between age or sex and between ELISA scores in 
BP patients and controls. Fig. 2 shows BP180 and BP230 
ELISA scores in BP and control sera. BP180 ELISA was 
positive in 46 (97.9%) patients with BP with a cut-off value 
of 9.0, which was previously determined by the manufac-
turer. Thirty-four (72.3%) BP patients were positive for 
BP230 ELISA. Of all BP patients, 13 (27.7%) were positive 
for only BP180 ELISA, one (2.1%) was positive for only 
BP230 ELISA and 33 (70.2%) were positive for both 
BP180 and BP230 ELISA. No BP patient was negative for 
both BP180 and BP230 ELISA. In the control group, one 
healthy volunteer and two EBA patients were positive for 
BP180 ELISA, and all control sera were negative for 
BP230 ELISA. The false positive sera of the control group 
showed low concentrations of ELISA score (18, 13.9 and 9 
U/ml) compared to the positive sera of BP patients. The 
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Fig. 4. Comparison of ELISA scores and clinical characteristics of BP patients. (A) BP180 ELISA scores and disease duration, (B) BP230 
ELISA scores and disease duration, (C) BP180 ELISA scores and disease severity grade, (D) BP230 ELISA scores and disease severity 
grade, (E) BP180 ELISA scores and pruritus severity grade, (F) BP230 ELISA scores and pruritus severity grade. BP: bullous pemphigoid, 
ELISA: enzyme-linked immunosorbent assay.
sensitivity and specificity of BP180 ELISA were 97.9% 
(46/47) and 90.3% (28/31), respectively. Those for BP230 
were 72.3% (34/47) and 100% (31/31). When the results 
of BP180 ELISA and BP230 ELISA were combined, sen-
sitivity and specificity reached 100% (47/47) and 90.3% 
(28/31), respectively. These results are summarized in 
Table 2.
Comparison of ELISA scores according to the clinical 
characteristics of BP
To determine clinical relevance, BP180 and BP230 ELISA 
scores were evaluated with respect to clinical characteris-
Usefulness of BP180 and BP230 ELISA
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Table 3. Comparison between the clinical characteristics and 
autoantibody reactivity against BP180 and BP230 in BP patients
BP180 and 
BP230
BP180 
only p-value
Disease duration ＜3 months 15 (46.9) 6 (50.0) 0.85
≥3 months 17 (53.1) 6 (50.0)
Disease severity Mild  7 (21.9) 2 (16.7) 0.45
 grade Moderate 18 (56.3) 5 (41.7)
Severe  7 (21.9) 5 (41.7)
Pruritus severity None  9 (28.1) 2 (16.7) 0.43
 grade Mild 11 (34.4) 7 (58.3)
Severe 12 (37.5) 3 (25.0)
Values are presented as n (%). BP: bullous pemphigoid.
Fig. 5. The index values of BP180 ELISA and BP230 ELISA and
titers of indirect immunofluorescence (IIF) in five BP patients 
before treatment and after remission. BP: bullous pemphigoid, 
ELISA: enzyme-linked immunosorbent assay.
tics. BP180 ELISA scores exhibited a significant correlation 
with disease activity scores (r=0.45, p=0.002, Fig. 3A) 
and peripheral blood eosinophil count (r=0.34, p=0.02, 
Fig. 3C), while BP230 ELISA scores did not (Fig. 3B and 
D). In addition, BP180 ELISA scores were significantly 
higher in BP patients with shorter disease duration (＜3 
months) compared to those with longer disease duration 
(≥3 months) (p=0.02, Fig. 4A). Between these two 
groups of patients, disease activity scores and presence of 
treatment showed no significant difference (data not 
shown). There was also a significant relationship between 
BP180 ELISA scores and the grade of disease severity 
(p=0.006, Fig. 4C) and pruritus severity (p=0.04, Fig. 4E). 
In contrast, BP230 ELISA scores did not show any 
significant relationship with the clinical characteristics of 
BP (Fig. 4B, D and E). We compared disease duration, 
disease severity grade, and pruritus severity grade 
between BP patients who were positive for both BP180 
and BP230 and patients who were positive for only 
BP180, using the chi-square or Fisher’s exact test (Table 
3). Between the two groups, there was no significant 
difference in disease duration, disease severity grade, and 
pruritus severity grade. One BP patient was positive only 
for the BP230 ELISA, and this patient did not show any 
different clinical features compared to other BP patients. 
Sequential comparison of ELISA scores, indirect IF 
titers, and disease activity scores in BP patients
To evaluate the usefulness of ELISA and indirect IF as 
indicators for BP disease activity, we compared the indi-
rect IF titers and ELISA scores before treatment and after 
complete remission in five BP patients. After remission, 
three patients (patients 1∼3) showed marked reductions 
in indirect IF titer and in both BP180 and BP230 ELISA 
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Fig. 6. (A, B) The index values of BP180 ELISA and BP230 ELISA, titers of indirect immunofluorescence (IIF) and disease activity
in one BP patient along the entire disease course. BP: bullous pemphigoid, ELISA: enzyme-linked immunosorbent assay.
scores. Patient 4 showed marked reductions in BP230 
ELISA score and indirect IF titer, but BP180 ELISA score 
was constantly negative throughout the study. Patient 5 
showed marked reductions in BP180 and BP230 ELISA 
scores, but indirect IF titer was constant (Fig. 5).
We also compared ELISA scores, indirect IF titers, and 
disease activity along the time course with patients whose 
serial sera and clinical records were available. The 
treatment began with methylprednisolone (＞30 mg/day) 
in addition to combination therapy such as mycopheno-
late mofetil (2.0 g/day), minocycline (100 mg/day), and 
dapsone (100 mg/day). After 2 years, ELISA scores and 
indirect IF titers decreased along with disease activity 
scores. In the following 2 months, although the ELISA 
scores and disease activity were nearly constant, the indi-
rect IF titer increased from 1：10 to 1：40. In our patient, 
while BP180 and BP230 ELISA scores fluctuated along 
with disease activity, indirect IF titers did not (Fig. 6).
DISCUSSION 
The pathogenic relevance of autoantibodies against BP180 
has been supported by several findings in both in vivo and 
in vitro studies. First, passive transfer of rabbit IgG anti-
bodies, raised against an extracellular region of murine 
BP180 homologous with the human immunodominant 
NC16A domain into neonatal mice induces all key fea-
tures of BP37. Second, in PG, a disease closely related to 
BP occurring during pregnancy, the transplacentar transfer 
of anti-BP180 autoantibodies from the mother into the 
neonate can cause a transient bullous eruption38. Third, 
the titer of autoantibodies against BP180 appears to be 
related to the activity and extent of the disease24,25,29-31. 
Based on these findings, it is considered that autoanti-
bodies to the extracellular domain of BP180 are pathoge-
nically critical in the development of BP. Several clinical 
and experimental studies suggested that anti-BP230 anti-
bodies may also play an important role in the onset of 
clinical symptoms and the formation of blisters39. First, 
rabbits immunized with BP230-derived peptides develo-
ped antibodies to the antigen, and, upon exposure to UVB 
light, they exhibited an enhanced inflammatory response, 
with IgG and C3 deposition at the BMZ40. Second, auto-
antibodies against BP230 were readily detected in the 
majority of patients, including those with relatively short 
disease duration. Third, neonatal mice that received sub-
cutaneous injection high-titer BP230-specific polyclonal 
rabbit IgG exhibited inflammatory response and skin fragi-
lity41. These findings suggest that autoantibodies against 
BP230 may bind to the target antigen in injured keratino-
cytes or even in intact ones by penetrating the cells, and 
possibly contribute to subepidermal blister formation and 
perpetuation of the disease41. However, a role of autoanti-
bodies against intracellular domains of BP230 and BP180 
in the development of BP has not been fully elucidated.
In this study, we examined the sensitivity and specificity 
of the BP180 and BP230 ELISA systems using BP sera 
along with two different control sera-EBA and normal sera. 
Since the antigen proteins in these ELISA systems are not 
in full length, there was a possibility that autoantibodies 
against other domains could not be detected. Neverthe-
less, similar to previous reports23, the BP180 ELISA 
showed positive reactivity in 46 (97.9%) of 47 BP sera 
samples. In contrast, only one serum sample out of 16 
EBA sera and two out of 15 normal control sera were 
positive, indicating the specificity of BP180 ELISA to be 
90.3%. The frequency of reactivity against BP180 in our 
BP sera was higher than previously reported ELISA sensi-
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tivities ranging from 80% to 94%23-25,27. This discrepancy 
may be attributed to the number of BP patients tested, the 
percentage of treated versus untreated patients, and the 
disease extent related to anti-NC16A IgG levels25,29-31. We 
also examined the reactivity of the BP230 ELISA in BP 
sera, EBA sera and normal control sera. The BP230 ELISA 
showed positive reactivity in 34 (72.3%) out of the 47 BP 
sera samples. In contrast, all EBA and normal control sera 
were negative, indicating 100% specificity. Most impor-
tantly, when the results of the BP230 ELISA and BP180 
ELISA were combined, the sensitivity rose to 100.0% 
(n=47). According to our data, all BP patients could be 
diagnosed using both the BP180 and BP230 ELISA. 
BP180 ELISA scores showed a significant relationship with 
disease activity, pruritus severity, peripheral blood eosino-
phil count, and disease duration, whereas BP230 ELISA 
scores did not. Previous studies demonstrated a corre-
lation between BP180 ELISA and disease activity of 
BP29,42,43. Peripheral blood eosinophil count was also 
significantly correlated with BP180 and BP230 ELISA 
scores44. In contrast, statistical analysis of our study de-
monstrated that BP180 ELISA scores relate to the blood 
eosinophil count, whereas BP230 ELISA scores do not. 
Such discordant findings require further study. The 
relationship between pruritus severity and titers of BP180 
and BP230, however, has never been demonstrated 
before. High peripheral blood eosinophil counts and 
severe pruritus are considered characteristic features of 
BP. Therefore, our findings provide further evidence of 
BP180 as an important pathogenic factor in BP. In addi-
tion, we also showed the relationship between the BP180 
ELISA score and disease duration. Patients with clinical 
lesions of BP persisting for 3 months or longer demon-
strated significantly lower BP180 ELISA scores compared 
to those who presented clinical lesions of BP for less than 
3 months. The two groups showed no significant diffe-
rence in disease activity and presence of treatment. Based 
on this finding, we suggest that autoantibody against the 
NC16A domain of BP180, located at the extracellular 
portion of BP180, may initiate and worsen the disease. 
After initiation of the disease, the exposure of the cyto-
plasmic proteins from damaged basal keratinocytes is 
suggested to boost production of autoantibodies against 
the cytoplasmic epitope of BP180 and BP230 based on 
the finding of an increase in anti-BP230 autoantibody 
levels in proportion to disease duration and during disease 
progression44. In contrast, since BP230 ELISA scores did 
not show a significant correlation with disease duration in 
our study, we concluded that the production of anti- 
BP230 has no relevance to disease progression.
We compared ELISA scores and indirect IF titers before 
treatment and after complete remission in five BP patients. 
Three of them (patients 1∼3) showed a significant decline 
in both ELISA scores and indirect IF titers at complete 
remission. Patient 4 was negative for BP180 ELISA before 
treatment and after complete remission. Interestingly, 
instead of the BP180 ELISA, the BP230 ELISA score 
decreased in parallel with the indirect IF titer. A similar BP 
patient with autoantibodies against BP230 but not for 
BP180 has been reported in a previous study44. Based on 
the finding that the BP230 score decreased along with 
disease activity score in this patient, IgG anti-BP230 
antibody may play a pathogenic role in these exceptional 
BP cases. Further study with a large number of BP patients 
with positivity to only BP230 is necessary to elucidate the 
pathogenic role of BP230. Patient 5 showed a significant 
decline in the ELISA score, but the indirect IF titer was 
constant. We also evaluated three serial sera taken from 
one BP patient at different time points, and compared 
them with clinical disease activity. The BP180 and BP230 
ELISA scores tended to fluctuate in parallel with the 
disease activity score along the time course and reflected 
disease severity, whereas the indirect IF titer did not. 
These observations suggest that when compared to indirect 
IF, which is subjective and known to depend greatly on 
the operator’s skill, ELISA could be a sensitive diagnostic 
tool and a sensitive monitoring tool for disease activity. 
Furthermore, recurrence was more likely to occur in 
patients who had high BP180 ELISA scores earlier24,29,31,43. 
Based on these findings, BP180 ELISA scores may be 
helpful to plan tapering schedules of corticosteroids and to 
predict flares or relapses by detecting increases in anti-
bodies before clinical evidence of disease flares are 
noticed. In addition to BP180 ELISA scores, BP230 ELISA 
scores also tended to fluctuate along with disease activity 
scores along the course of the disease in our study. Further 
study is needed to confirm our finding of the role of 
BP230 ELISA in monitoring disease activity of BP.
Our data show that currently available commercial ELISA 
kits for detection of autoantibodies against BP180 and 
BP230 have optimal diagnostic accuracy. Both methods 
have very high specificity, and BP180 ELISA, in particular, 
is more sensitive than BP230 ELISA. However, several BP 
patients showed negative findings for BP180 or BP230 
ELISA. This finding may be explained by the existence of 
additional epitopes in BP180 and BP230. Therefore, to 
improve diagnostic sensitivity of ELISA, additional epito-
pes of the intracellular and extracellular portions of BP180 
and BP230 should be included in the antigen molecules 
of ELISA. Based on thorough statistical analysis, our 
findings demonstrate that BP180 ELISA scores relate to the 
disease activity of BP, whereas BP230 ELISA scores do 
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not. In addition to disease activity, BP180 ELISA score 
showed significant correlation with pruritus severity and 
peripheral blood eosinophil count, which are charac-
teristic clinical features of BP. We also found that the 
ELISA scores showed parallel fluctuation with the disease 
activity along the time course, whereas the indirect IF titer 
did not.
Our findings may enhance the role of anti-BP180 autoanti-
body in the pathogenesis of BP, particularly by revealing 
the positive relationship between BP180 ELISA scores and 
several typical features of BP, including increased periphe-
ral blood eosinophil count and pruritus severity. Although 
BP230 ELISA showed lower sensitivity than BP180 ELISA, 
BP230 ELISA was helpful in improving the sensitivity 
when used in combination with BP180 ELISA. 
In conclusion, the ELISA systems for the detection of reac-
tivity to both BP180 and BP230 are useful diagnostic and 
perhaps even monitoring tools for BP and may replace 
indirect IF using skin sections.
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